Only animal studies have shown beneficial effects of magnesium sulfate in perinatal asphyxia.
P ERINATAL ASPHYXIA OCCURS in 1% to 1.5% of live births in developed countries. 1 In developing countries, the incidence of perinatal asphyxia is greater; in India, the National Neonatal Perinatal Database reported an incidence of 5% among studies conducted in 16 medical institutes. 2 Encephalopathy occurs in 50% to 60% of patients with severe perinatal asphyxia. 3 Moderate/severe hypoxic-ischemic encephalopathy (HIE) causes significant morbidity and death in the neonatal period and permanent neurodevelopmental handicaps among survivors. 4 Among patients with moderate HIE, 10% to 20% die and 30% to 40% develop neurodeficits, whereas 50% of patients with severe HIE die and almost all survivors develop neurodeficits. 5, 6 Neurologic abnormality at discharge is a strong predictor of long-term neurodevelopmental delay. 7 Studies mainly with animal models have elucidated 2 phases of hypoxic-ischemic brain injury, and each phase is characterized by energy depletion. Primary neuronal injury occurs during the process of asphyxia and stops with resuscitative measures. Secondary neuronal injury continues for hours to days, even after reversal of the asphyxial event, and many factors are involved in this phase of neuronal death, with excitotoxicity being one of the important mechanisms. 8 Glutamate acts on the N-methyl-D-aspartate (NMDA) receptor, a postsynaptic ion channel in the brain. During asphyxia, there is excessive release and reduced uptake of glutamate in the newborn brain. High concen-trations of glutamate open NMDA channels, allowing excessive calcium influx into the neurons and inducing irreversible neuronal injury. 9 This secondary phase may last as long as 72 hours. 10 Magnesium is a naturally occurring NMDA receptor antagonist that blocks neuronal influx of calcium within the ion channels. 11 This block is voltage dependent and is overcome during axonal depolarization, which occurs with hypoxic-ischemia. If the extracellular concentration of magnesium is increased, then this block can be restored. 12 Review of the literature regarding the effects of magnesium after simulated hypoxic-ischemic insults in several animal models revealed beneficial effects in some studies [13] [14] [15] and no effect in others. 16, 17 Magnesium sulfate is widely used as a tocolytic agent and for suppression of pregnancy-induced hypertension, and it has shown beneficial effects in neonates born to treated women. A collaborative eclampsia trial 18 reported that infants born to mothers who received magnesium sulfate before delivery were less likely to be intubated or to be admitted to ICUs. However, there is a paucity of literature regarding the role of magnesium sulfate in term neonates with perinatal asphyxia, and only 1 study showed beneficial results. 19 We performed a randomized, controlled trial to test whether postnatal magnesium sulfate treatment could improve neurologic outcomes at discharge for term neonates with severe perinatal asphyxia.
METHODS
This was a randomized, placebo-controlled trial conducted in the NICU of Sheri Kashmir Institute of Medical Sciences (Srinagar, India), which is a tertiary-care hospital in northern India. On the basis of our previous study, it was estimated that 40 neonates with moderate/ severe HIE needed to be studied to allow detection of a 50% reduction in the rate of adverse outcomes with 80% power. These 40 neonates were born in the obstetric department of Sheri Kashmir Institute of Medical Sciences between September 2004 and August 2006. Infants were enrolled after parental consent was obtained; the study was approved by the hospital ethics committee.
Infants eligible for the study had gestational ages of Ն37 weeks, were Ͻ6 hours of age at the time of admission, had HIE (moderate or severe), and had severe perinatal asphyxia, as manifested by 3 of the following 4 criteria: (1) history of fetal distress (late deceleration, loss of beat-to-beat variability, fetal bradycardia, or meconium-stained amniotic fluid), (2) need for immediate neonatal ventilation with a bag and mask or through endotracheal intubation for Ն2 minutes after delivery, (3) 5-minute Apgar score of Ͻ6, or (4) base deficit of Ն15 mEq/L or pH of Յ7 in cord blood or admission arterial blood samples within the first hour after birth. Moderate or severe HIE was diagnosed for these neonates when Ն1 sign was present in 3 of the following 6 categories: (1) Patients with severe intrauterine growth retardation, any condition unrelated to asphyxia, age of Ͼ6 hours at admission, maternal prenatal magnesium administration, metabolic disorder, chromosomal anomalies, or congenital malformations were excluded from the study.
These infants were assigned randomly, with computer-generated random numbers, to receive either magnesium sulfate infusion (treatment group) or normal saline infusion (placebo group). The investigators and caregivers were blinded to the assignment of patients. The asphyxia score (range: 0-9) described by Portman et al, 20 which is based on fetal heart rate, 5-minute Apgar score, and base deficit during the first hour of life, was used to quantitate the severity of asphyxia, and prevalence rates of multiorgan dysfunction were compared. The score for moderate asphyxia is 5, and that for severe asphyxia is Ͼ6.
Infants in both the treatment and placebo groups were nursed on servo-controlled, open-care beds, with skin temperature maintained at 36.5°C. On day 1 of life, 10% dextrose solution was administered as the maintenance intravenous fluid; electrolytes were added from day 2 of life. Only two thirds of the maintenance fluids were administered initially, until the syndrome of inappropriate antidiuretic hormone secretion was ruled out. Electrolyte measurements and renal function tests were performed daily for the first 5 days of life and subsequently depending on the condition of the infant. Respiratory support in the form of oxygen therapy or ventilation was provided as and when needed. Presser support in the form of dopamine or dobutamine administration was provided as and when needed. The treatment group also received magnesium sulfate infusion at 250 mg/kg per dose (1 mL/kg per dose in 20 mL of 5% dextrose solution) over 1 hour, with 2 additional doses repeated at intervals of 24 hours. 21 The placebo group received 3 doses (1 mL/kg per dose) of normal saline solution in 20 mL of 5% dextrose solution, 24 hours apart.
During the initial 72 hours of life, heart rate, respiratory rate, and oxygen saturation were monitored continuously. Blood pressure was monitored during magnesium sulfate infusion and for the subsequent 24 hours through invasive blood pressure monitoring. Blood pressure was monitored subsequently with a noninvasive blood pressure-monitoring system. Clinical assessments included assessments of the neurologic status at admission and during the stay, the grade of HIE (moderate or severe), the type of respiratory support needed, the presence of seizures, and the time for establishment of full oral feedings through sucking, as well as a neurologic examination at discharge. 22 The neurologic examination was performed by certified clinicians who were blinded to the group assignment of the patients. Laboratory assessments included measurements of serum magnesium, lactate dehydrogenase, and creatine kinase levels, liver function tests, including measurements of aspartate aminotransferase and alanine aminotransferase levels, electrocardiography, echocardiography, neuroimaging (computed tomography [CT] of the head), and electroencephalography. Serum magnesium levels were concealed from the clinicians caring for these neonates. Electroencephalography was performed initially within 72 hours after admission and was repeated at day 14 to assess normalization or persistence of abnormalities. Any electroencephalogram showing constant low voltage, electrocerebral inactivity, or burst suppression was reported as abnormal. Initial head CT was performed on day 3 of life, to look for hypoattenuation of deep nuclear structures, hemorrhage, or both. Follow-up head CT was performed at 14 days of life, to assess the evolution of initial findings or the appearance of distinct abnormal signs (Ͼ2 focal hypodensities, diffuse hypodensity with or without ventricular effacement, hyperdense lesions in basal ganglia, or encephalomalacia). 7 Analysis of variance, Fisher's exact test, and the 2 test were used for data analysis. The data are presented as mean Ϯ SD.
RESULTS
A total of 70 neonates were screened in 48 months. Thirty neonates were excluded (inclusion criteria not fulfilled for 20 neonates, parents refused to participate for 6 neonates, and other causes for 4 patients). Forty neonates fulfilled the inclusion criteria and constituted the study group. Twenty neonates were assigned randomly to the treatment group and 20 to the placebo group. There were 21 male patients and 19 female patients. There were no differences in gestational age, birth weight, gender, mode of delivery, individual components of the asphyxia score (fetal heart rate, 5-minute Apgar score, and base excess), blood pH, or blood pressure between the treatment and placebo groups ( Table  1) .The groups received an initial infusion of either magnesium sulfate or an equal volume of placebo solution, at similar chronologic ages (treatment group: 2.9 hours; placebo group: 2.5 hours). Among patients in the treatment group, 35% had moderate HIE and 65% had severe HIE at admission. In the placebo group, 40% of patients had moderate HIE and 60% had severe HIE. Eleven (55%) of 20 patients in the treatment group needed assisted ventilation, compared with 12 (60%) of 20 patients in the placebo group (P Ͼ .05). Presser support was needed by 35% (7 of 20) of patients in the treatment group, compared with 25% (5 of 20) of patients in the placebo group (P Ͼ .05).
The serum magnesium levels for the treatment and placebo groups were comparable at 0 hours, but levels for the treatment group were higher (P Ͻ .05) at 1, 23, 25, 47, 49, and 72 hours. In the treatment group, the mean serum magnesium concentration increased from 0.77 mmol/L at 0 hour to 1.5 mmol/L within 1 hour after the first dose, from 1.2 to 2.2 mmol/L within 1 hour after the second dose, and from 1.4 to 2.8 mmol/L within 1 hour after the third dose of magnesium sulfate. Therefore, the mean serum magnesium concentration remained at Ն1.2 mmol/L during the initial 72 hours after the first infusion.
There was no significant difference in mean arterial pressures between the treatment and placebo groups (45.4 Ϯ 4 vs 45.5 Ϯ 4.8 mm Hg) at admission (P Ͼ .05). No significant decrease in mean arterial pressure occurred during the first 72 hours of life, during which 3 doses of magnesium sulfate were administered in the treatment group. Two patients in the treatment group developed apnea during the second dose of magnesium sulfate, which necessitated intubation and temporary ventilatory support.
Characteristics of the hospital course and the status at discharge are shown in Table 2 . The numbers of patients with renal involvement, pulmonary hypertension, hypotension requiring presser support, and hepatic dysfunction (aspartate aminotransferase level of Ͼ120 IU and alanine aminotransferase level of Ͼ135 IU) were similar for the 2 groups. Two (10%) of 20 patients in the treatment group died during the hospital stay. The 2 patients had severe HIE at admission and underwent ventilation from the time of admission. Both were brain dead at 72 hours of life, and they died on day 5 and day 6 of life. In the placebo group also, 2 (10%) of 20 patients died. One patient died on day 3 of life and another on day 9 of life; both had severe HIE. Abnormal CT findings included basal ganglia injury (2 patients in the treatment group and 3 patients in the control group), cortical injury (1 patient in the treatment group and 2 patients in the control group), and injury to both cortical and subcortical areas (3 patients in the control group). Electroencephalographic abnormalities were seen for 22% (4 of 18) of patients in the treatment group, compared with 33% (6 of 18) of patients in the placebo group (OR: 0.57 [95% CI: 0.12-2.5]). Feedings (oral or tube) were initiated by the seventh day for 55% (10 of 18) of patients in the treatment group, compared with 38% (7 of 18) of patients in the placebo group. At discharge, 14 (77%) of 18 patients in the treatment group were receiving oral feedings (sucking), compared with 7 (37%) of 18 patients in the placebo group (OR: 0.18 [95% CI: 0.04 -0.78]; P Ͻ .02). Good short-term outcomes (a composite measure of no neurologic abnormality, normal neuroimaging findings, normal electroencephalographic findings, and oral feeding through sucking) at discharge were seen for 77% of patients (14 of 18) in the treatment group, compared with 37% (7 of 18) of patients in the placebo group (OR: 5.5 [95% CI: 1.2-23.6]; P Ͻ .02).
DISCUSSION
Our study shows that postnatal magnesium sulfate treatment improves neurologic outcomes at discharge for term neonates with HIE. Magnesium sulfate is neuroprotective because Mg 2ϩ ions gate the NMDA receptor, thereby reducing the Ca 2ϩ influx that can trigger cell death. 23 However, this block is voltage dependent and is overcome during the axonal depolarization that occurs with hypoxic-ischemia. If the extracellular magnesium concentration is increased, then this blockade can be restored. 11 In our study, the mean serum magnesium concentration remained at Ն1.2 mmol/L, which is in the therapeutic range. 24 Furthermore, we used 3 doses of magnesium sulfate (250 mg/kg per dose), 24 hours apart, because secondary neuronal injury can last as long as 72 hours. 10 Postnatal magnesium sulfate infusion was neuroprotective in our study. This was reflected by fewer neonates with neurologic abnormalities and more infants receiving oral feedings at discharge in the treatment group. However, the neuroimaging results were not significant. This could be attributable to the small number of patients. Also, the best neuroimaging modality for HIE is MRI (diffusion-weighted images), and that modality was not available to our patients during the study period. Because MRI of the brain is more sensitive and specific than CT in HIE, more infants with abnormal neuroimaging results likely would have been identified with that modality.
The overall mortality rate in our study was 10%. The mortality rate for our patients was lower than that in previously published studies, 25 and the most likely reason is that life support was withdrawn for no infant. Also, the number of patients was too small to enable evaluation of a significant effect of magnesium sulfate on survival rates. Although we did not observe any decrease in blood pressure during or after magnesium sulfate infusion, 2 of our patients developed apnea and required ventilation, which confirms that adverse effects can occur during infusion and intense monitoring is needed.
The entry criteria for our study consisted of clinical and biochemical parameters and did not include the use of amplitude-integrated electroencephalography. In our study, however, a very high-risk population was included on the basis of clinical, biochemical, and neurologic criteria, as confirmed by 4 deaths, the need for mechanical ventilation immediately after birth for 23 patients, 14 patients surviving with neurologic abnormalities, and 11 patients with abnormal CT findings at discharge. The protective role of magnesium sulfate has been based largely on studies with animal models, many of which showed favorable results in terms of amelioration of secondary neuronal injury. [13] [14] [15] A few studies with pregnant women showed beneficial effects for neonates also. Nelson and Grether 26 observed a lower incidence of cerebral palsy in preterm infants born to mothers who had received magnesium sulfate before delivery. Schendel et al 18 and Grether et al 27 observed the relationship of intrapartum magnesium sulfate administration to mothers and cerebral palsy in newborns. They showed significant effects of magnesium sulfate in preventing cerebral palsy. Harrison et al 28 reported lower incidences of fetal heart rate deceleration and term stillbirths for mothers who received magnesium supplementation during pregnancy. However, there was no effect on the incidence of HIE, because it was an underpowered study and compliance was poor among the study population.
There has been only 1 postnatal human trial regarding the role of magnesium sulfate in neonates with perinatal asphyxia. 19 The study showed good outcomes among patients treated with magnesium sulfate in the immediate neonatal period. However, it was not a placebo-controlled trial. Our study is the first placebo-controlled trial that shows improved neurologic outcomes at discharge in the magnesium sulfate group. Good shortterm outcomes at discharge, the composite measure of all parameters, were statistically significant (P Ͻ .02), although individual components except neurologic abnormalities and oral feeding (sucking) were not significant (because of the small number of patients).
The role of magnesium sulfate in neuroprotection also is being evaluated in acute traumatic brain injury, in both adults and children. In a recent study, magnesium sulfate administration to children with severe traumatic brain injuries did not decrease cerebral perfusion pressure or mean arterial pressure and had no adverse effects on cardiac conduction. 29 Although 1 study in adults showed no beneficial effects of magnesium sulfate after traumatic brain injury, 30 many other studies are being conducted to test the neuroprotective abilities of magnesium sulfate in acute trauma.
CONCLUSIONS
Postnatal magnesium sulfate infusion is effective in improving outcomes for infants with severe perinatal asphyxia when it is given early (within 6 hours) and, in combination with other modalities of treatment (hypothermia) during the therapeutic window, it could be very beneficial. However, more studies with larger sample sizes, preferably multicenter trials, are needed to confirm the results.
